Phosphoric acid, diphenyl ester

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:29466770	IVR	0.2 mg/day	0.2 mg/day	Affects lipid metabolism	Metabolic endocrine-mediated perturbations
	IVR	0.2 mg/day	0.2 mg/day	Affects glucose metabolism	Metabolic endocrine-mediated perturbations
	IVR	0.2 mg/day	0.2 mg/day	Affects gluconeogenesis	Metabolic endocrine-mediated perturbations
	IVR	0.002 mg/day	0.002 mg/day	Affects glucose metabolism	Metabolic endocrine-mediated perturbations
	IVR	0.002 mg/day	0.002 mg/day	Affects lipid metabolism	Metabolic endocrine-mediated perturbations
	IVR	0.002 mg/day	0.002 mg/day	Affects gluconeogenesis	Metabolic endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.